Story

On air. The free wire runs 15 minutes behind live. See pricing

World, crypto, finance and tech news, scored for impact.

MarketsSEC EDGAR SCHEDULE 13GFiled 3 days ago

ASSEMBLY BIOSCIENCES, INC.: Janus Henderson Group Ltd. amends Schedule 13G stake filing

Open the sourceReported by SEC EDGAR SCHEDULE 13G, sec.gov, 16 November 2026, by SEC EDGAR SCHEDULE 13G

Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.

Janus Henderson Group Ltd. amended its Schedule 13G filing for Assembly Biosciences, Inc., updating its beneficial ownership stake with the SEC under accession number 0001274173-26-000264. The filing was disclosed via SEC EDGAR and reflects a change to the institutional investor's previously reported position in the clinical-stage biopharmaceutical company. Schedule 13G amendments are typically filed when a passive investor's ownership percentage crosses reporting thresholds or when holdings change materially. The specific revised share count and ownership percentage were not detailed in the headline disclosure. Investors will watch for the full filing details to gauge Janus Henderson's current position in Assembly Biosciences and any signal about institutional conviction in the stock.

Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.

Named in this story

Janus Henderson Group Ltd., Assembly Biosciences, Inc.